INTERIM REPORT Q1 2020
Summary Financial overview January 1 – March 31, 2020 · Net sales amounted to SEK 0.0 M (0.0) · Loss for the period was SEK 297.3 M (loss: 134.1) · Loss per share, before and after dilution, was SEK 5.37 (loss: 2.82) · On March 31 cash and cash equivalents amounted to SEK 617.8 M (747.5) Significant events during the period January 1 – March 31, 2020 · Top line results from the company’s pivotal phase 2 study HORIZON were presented and showed a 26% Overall Response Rate (ORR) of melflufen in triple-class refractory multiple myeloma patients · The Lancet